Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas

• Published in: Cancer cell Vol. 42; no. 5; pp. 833 - 849.e12
• Main Authors: Choi, Jaewoo, Ceribelli, Michele, Phelan, James D., Häupl, Björn, Huang, Da Wei, Wright, George W., Hsiao, Tony, Morris, Vivian, Ciccarese, Francesco, Wang, Boya, Corcoran, Sean, Scheich, Sebastian, Yu, Xin, Xu, Weihong, Yang, Yandan, Zhao, Hong, Zhou, Joyce, Zhang, Grace, Muppidi, Jagan, Inghirami, Giorgio G., Oellerich, Thomas, Wilson, Wyndham H., Thomas, Craig J., Staudt, Louis M.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 13.05.2024
• Subjects: ABC; B cell receptor; combination therapy; CSK; dexamethasone; DLBCL; GCB; glucocorticoids; PI3 kinase; prednisone; dexamethasone; DLBCL; ABC; PI3 kinase; GCB; combination therapy; CSK; glucocorticoids; B cell receptor; prednisone

Glucocorticoids have been used for decades to treat lymphomas without an established mechanism of action. Using functional genomic, proteomic, and chemical screens, we discover that glucocorticoids inhibit oncogenic signaling by the B cell receptor (BCR), a recurrent feature of aggressive B cell mal...